^
Association details:
| Biomarker: | HLA-A*02:01 |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | TAEST16001 (TCR modulator, NY ESO 1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Study of TAEST16001 in Soft Tissue Sarcoma
Excerpt:
...- Genotype and tumor antigen screening must meet the following 2 criteria: HLA-A*02:01 positive; NY-ESO-1* positive: immunohistochemical staining positive cells are ≥20%;...
Trial ID:
Source:
Title:
Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma
Published date:
05/26/2022
Excerpt:
Here, we report preliminary results of TAEST16001 cells from an ongoing, dose-escalation and expansion study in HLA-A*02:01 positive patients with advanced soft tissue sarcoma expressing NY-ESO-1 antigen. Among 12 efficacy-evaluable patients, 5 patients had a partial response, 5 patients had stable disease, and 2 patients had progressive disease. The overall response rate was 41.7%. The median time to an initial response was 1.9 month (range, 0.9 to 3.0), and the median duration of response was 14.1 months (range, 5.0 to 14.2).
DOI:
10.1200/JCO.2022.40.16_suppl.11502
Trial ID:
